GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Faes Farma SA (OTCPK:FSXMF) » Definitions » EV-to-EBIT

Faes Farma (Faes Farma) EV-to-EBIT : 8.24 (As of May. 26, 2024)


View and export this data going back to . Start your Free Trial

What is Faes Farma EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Faes Farma's Enterprise Value is $882.96 Mil. Faes Farma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $107.21 Mil. Therefore, Faes Farma's EV-to-EBIT for today is 8.24.

The historical rank and industry rank for Faes Farma's EV-to-EBIT or its related term are showing as below:

FSXMF' s EV-to-EBIT Range Over the Past 10 Years
Min: -35.36   Med: 11.9   Max: 25.3
Current: 11.08

During the past 13 years, the highest EV-to-EBIT of Faes Farma was 25.30. The lowest was -35.36. And the median was 11.90.

FSXMF's EV-to-EBIT is ranked better than
67.86% of 672 companies
in the Drug Manufacturers industry
Industry Median: 16.985 vs FSXMF: 11.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Faes Farma's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil. Faes Farma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $107.21 Mil. Faes Farma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.


Faes Farma EV-to-EBIT Historical Data

The historical data trend for Faes Farma's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Faes Farma EV-to-EBIT Chart

Faes Farma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.93 10.60 10.34 10.07 -

Faes Farma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.72 10.07 9.39 9.45 -

Competitive Comparison of Faes Farma's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Faes Farma's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Faes Farma's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Faes Farma's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Faes Farma's EV-to-EBIT falls into.



Faes Farma EV-to-EBIT Calculation

Faes Farma's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=882.961/107.209
=8.24

Faes Farma's current Enterprise Value is $882.96 Mil.
Faes Farma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $107.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faes Farma  (OTCPK:FSXMF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Faes Farma's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 ) =EBIT / Enterprise Value (Q: Jun. 2023 )
=107.209/0
= %

Faes Farma's Enterprise Value for the quarter that ended in Jun. 2023 was $0.00 Mil.
Faes Farma's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $107.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Faes Farma EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Faes Farma's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Faes Farma (Faes Farma) Business Description

Traded in Other Exchanges
Address
Maximo Aguirre, 14, Leioa, Vizcaya, ESP, 48940
Faes Farma SA is a pharmaceutical company that specializes in the research, production, distribution, and sale of prescription and generic drugs, over-the-counter medicines, food supplements and personal care treatments, as well as raw materials for the pharmaceutical use. The company develops new drugs for the treatment of allergy, venous insufficiency, and irritable bowel syndrome. It also provides animal nutrition products. Faes Farma exports its products to more than 60 countries and has operations in Spain, Portugal, Chile, and Mexico, among others.

Faes Farma (Faes Farma) Headlines

No Headlines